Amneal Pharmaceuticals, Inc.
NASDAQ:AMRXDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $7.62B
- Beta
- 1.32
- P/E (TTM)
- 43.4
- EPS (TTM)
- $0.37
Volume 1.91M
Average 1.75M
AMRX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Amneal Pharmaceuticals, Inc.NASDAQ: AMRX
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $148.72M rose 19.7% year over year, ahead of the +16.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.1% from the prior quarter. Over 3 fiscal years it compounded at +9.6% a year.
Context
- Selling, general & admin amounted to 17.5% of revenue in FY2025, up 0.4 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $565.06M (+7.3%) for the fiscal year ending Dec 2026, a slowdown from the +10.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $148.72M+7.1% QoQ
- Last fiscal yearDec 2025
- $526.83M+10.6% YoY
- LTMJun 2026
- $571.86M+16.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.7% | +4.4% | -15.3 pp |
| 1 year | +10.6% | +7.3% | -3.3 pp |
| 3-year CAGR | +9.6% | +9.0% | -0.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 526.83M USD
- Year-over-year change
- +10.6%
- 4-year CAGR
- +9.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 526.83M | +10.6% |
| FY2024 | 2024-12-31 | 476.44M | +10.9% |
| FY2023 | 2023-12-31 | 429.68M | +7.5% |
| FY2022 | 2022-12-31 | 399.7M | +9.4% |
| FY2021 | 2021-12-31 | 365.5M | — |
Selling, General & Admin vs competitors
How AMRX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +16.7% is the 3rd highest of 11, against a peer median of +11.4%.
- Selling, general & admin amounts to 18.3% of revenue for AMRX, versus a peer median of 29.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹112.14B INR | +14.7% | +18.2% | 33.8% | |
| LTM Jun 2026 | $4.13B USD | +9.9% | +4.9% | 23.8% | |
| LTM Jun 2026 | $3.98B USD | +1.3% | -3.2% | 27.0% | |
| LTM Jun 2026 | $3.45B USD | +0.5% | +10.7% | 31.7% | |
| LTM Jun 2026 | $571.86M USD | +16.7% | +9.6% | 18.3% | |
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | $534M USD | +18.4% | +10.6% | 40.1% |
| LTM Jun 2026 | $331.4M USD | -68.8% | -24.2% | 8.0% | |
| LTM Mar 2026 | $314.87M USD | +13.2% | +36.8% | 34.1% | |
| LTM Mar 2026 | $180.5M USD | -32.3% | -18.1% | 26.7% | |
| LTM Mar 2026 | $131.9M USD | +35.5% | +24.9% | 18.3% | |
| LTM Mar 2026 | $31.97M USD | +12.9% | +5.0% | 76.2% | |
| Peer median (excluding AMRX) | — | +11.4% | +7.8% | 29.4% | |
Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.09B | 2.21B | 2.39B | 2.79B | 3.02B |
| Cost of Revenue | 1.32B | 1.42B | 1.53B | 1.77B | 1.88B |
| Gross Profit | 768.97M | 791.46M | 863.87M | 1.02B | 1.14B |
| Gross Margin | 36.7% | 35.8% | 36.1% | 36.5% | 37.6% |
| Research & Development | 209.56M | 208.66M | 194.75M | 190.71M | 186.18M |
| Selling, General & Admin | 365.5M | 399.7M | 429.68M | 476.44M | 526.83M |
| Operating Expenses | 616.26M | 886.39M | 659.5M | 771.11M | 713M |
| Depreciation & Amortization | 233.41M | 240.18M | 229.4M | 236.19M | 223.57M |
| EBITDA | 401.1M | 440.21M | 500.78M | 439.77M | 603.87M |
| EBITDA Margin | 19.2% | 19.9% | 20.9% | 15.7% | 20.0% |
| Operating Income | 152.72M | (94.93M) | 204.37M | 249.33M | 423.09M |
| Operating Margin | 7.3% | -4.3% | 8.5% | 8.9% | 14.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 136.33M | 158.38M | 210.63M | 258.6M | 241.09M |
| Other Income / Expenses | (121.35M) | (153.2M) | (244.64M) | (304.34M) | (283.88M) |
| Income Before Tax | 31.37M | (248.13M) | (40.27M) | (55.01M) | 139.21M |
| Pre-Tax Margin | 1.5% | -11.2% | -1.7% | -2.0% | 4.6% |
| Income Tax Expense | 11.2M | 6.66M | 8.45M | 18.86M | 11.28M |
| Net Income | 10.62M | (129.99M) | (83.99M) | (116.89M) | 72.06M |
| Net Margin | 0.5% | -5.9% | -3.5% | -4.2% | 2.4% |
| EPS (Basic) | 0.07 | (0.86) | (0.48) | (0.38) | 0.23 |
| EPS (Diluted) | 0.07 | (0.86) | (0.48) | (0.38) | 0.22 |
| Weighted Avg Shares | 148.92M | 150.94M | 174.99M | 308.98M | 313.37M |
| Weighted Avg Shares (Diluted) | 151.82M | 150.94M | 176.14M | 308.98M | 324.81M |
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
Intrinsic Alpha fair value
Locked
Current Price
$21.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.